OR WAIT null SECS
Susan Haigney is managing editor of BioPharm International, susan.haigney@ubm.com.
May 30, 2024
The company’s new division will provide end-to-end integrated discovery services.
Bkemv (eculizumab-aeeb) is the first interchangeable biosimilar to Soliris (eculizumab) to treat paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
May 29, 2024
The partnership will create therapeutic assets and new discovery platforms and potentially reshape drug discovery.
May 23, 2024
The units are being recalled because of incomplete crimp seals and one complaint of a leaking unit.
May 22, 2024
The company is collaborating with the Access to Oncology Medicines Coalition to expand patient access to immuno-oncology therapy Opdivo.
May 20, 2024
The new facility will be the company’s first to offer full manufacturing processing for antibody drug conjugates.